Capital CDC Customer Honored as SBA's Houston District "Small Business Person of the Year" - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Capital CDC Customer Honored as SBA's Houston District "Small Business Person of the Year"


Capital CDC Customer Honored as SBA's Houston District "Small Business Person of the Year"

PR Newswire

AUSTIN, Texas, April 28, 2014 /PRNewswire-USNewswire/ -- The U.S. Small Business Administration (SBA) has named Dr. Nawab Baloch - President and CEO of Clinical Trial Network, a clinical research company – the 2014 Houston District "Small Business Person of the Year". Dr. Baloch's company employs over 100 people with sales in excess of $2.4 million

Clinical Trial Network, LLC (CTN) is a privately owned Multi Specialty Clinical Research (MSCR) facility that collects crucial and vital clinical trial data for pharmaceutical and biotech companies for submission to FDA in order to get approval for new drug and devices. Clinical Trial Network - under the experienced leadership of Nawab F. Baloch M.D. - has developed a proven, streamlined, and scalable business model that delivers quantity and quality.

Utilizing the SBA 504 Loan Program, CTN was able to open a high-volume, low-cost, affordable, family practice clinic with diagnostic services to serve its existing patient database and generate new patients for research studies. Additionally, CTN opened 3 satellite centers in different parts of the Greater Houston area so as to offer the capabilities to different section of the population and achieve an aggressive growth in the clinical research sector.

Capital CDC would like to congratulate Dr. Nawab Baloch on all of his success! We are proud to have partnered with Chase Bank to finance this loan through the SBA 504 Loan Program. We look forward to seeing him honored at the upcoming Small Business Awards Luncheon in Houston, Texas.

CONTACT: Kelly Acosta, 512-615-0398, Kellyacosta@capitalcdc.com

SOURCE Capital CDC

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here